Authors of a recent article in Nature Reviews Clinical Oncology describe the clinical and mechanistic manifestations of secondary cancers that have thus far been observed to arise as a consequence of BRAF inhibition. They discuss the concept of pre-existing populations of partly transformed cells with malignant potential that might be present in various organ systems, and the rationale for novel therapeutic strategies for the management of BRAF-inhibitor-induced neoplasia. Read more here.
Study mentioned: Gibney GT, et al. Paradoxical oncogenesis-the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol. 2013 Jul;10(7):390-9. PMID: 23712190
No comments:
Post a Comment